IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: G. CONNOR

Serial No.: NOT YET ASSIGNED Art Unit: NOT YET ASSIGNED

Filed : January 23, 2004 Examiner: NOT YET ASSIGNED

For : COMBINATION THERAPY COMPRISING ANTI-DIABETIC AND

ANTICONVULSANT AGENTS

I hereby certify that this correspondence is being deposited with the United States Postal Service as express mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

January 23, 2004
(Date of Deposit)

MARY A. APPOLLINA (Name of applicant, assignee, or Registered Representative)

JANUARY 23, 2004

(Date of Signature)

Mail Stop Patent Application Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this

information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

In accordance with §1.97(b), since this Information

Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in $\S1.491$, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required. In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with [] the first or Second After Final Submission, therefore: Statement in Accordance with §1.97(e) (attached); or Please charge Deposit Account No. 10the fee of \$180.00 as set forth in $\S1.17(p)$. In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth

in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

☐ St	tatement in Accordance with §1.97(e)
(6	attached); or
P]	lease charge Deposit Account No. 10-
0.5	750/ / the fee of $$180.00$ as set forth
ir	n §1.17(p).
-	
	ordance with §1.97(d), this Information
	ment is being filed after the mailing date of
either a Final Ac	ction under §1.113 or a Notice of Allowance
under §1.311 but	before the payment of the Issue Fee.
Applicant(s) here	eby petition(s) for consideration of this
Information Discl	osure Statement. Included are: Statement in
Accordance with \S	1.97(e) as set forth below and the fee of
\$180.00 as set fo	orth in §1.17(p).
	of each of the references listed on the
	0-1449 are enclosed herewith with the exception
	Insulin Resistance Syndrome, The Monitor,
	6, which was cited by the Office in the parent
	2,425 filed October 25, 2001, relied on for an
	e filing date under 35 U.S.C.§120.
carrier cricective	Filling date dilder 33 0.8.e.g.zv.
<pre>Copies</pre>	of references listed on the attached Form PTO-
1449 are enclosed	herewith EXCEPT THAT:
_ Ir	n view of the voluminous nature of references
	list as appropriate], and the likelihood that
	nese references are available to the Examiner,
CC	opies are not enclosed herewith.
□ т <i>f</i>	f any of the foregoing publications are not
	vailable to the Examiner, Applicant will
	ndeavor to supply copies at the Examiner's
	equest.
re	Adaese.

n patent documents and non-
in accordance with 37 CFR 1.98
each U.S. patent application
ned Form PTO-1449 are not
nt application was filed after
onal application has entered the
L after June 30, 2003 (see USPTO
CFR 1.98 (a)(2)(i).
eferences which are not in the
e listed references which are
as follows:
f search report(s) from
n(s), which are listed on the
509 D.
owing non-published pending
e deemed relevant, which are
on Under MPEP 609 D.
ay or gradit any ayarnaymant to
cy or credit any overpayment to
-1520-USA-CNT/MAA. This form is
espectfully submitted,
Mary a. Orppoller
ary/A. Appollina eq. No. 34,087
ttorney for Applicants

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (732) 524-3742 DATED: January 23, 2004

.

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 1 of 2

0	a collection of information unless it displays a valid OMB control number.				
	Application Number	NOT YET ASSIGNED			
	Filing Date	JANUARY 23, 2004			
	First Named Inventor	G. CONNOR			
	Group Art Unit	NOT YET ASSIGNED			
	Examiner Name	NOT YET ASSIGNED			
	Attorney Docket Number	ORT-1520-USA-CNT			
	-				

U.S. PATENT DOCUMENTS						
	Cite No.1	U.S. Patent Document			Date of Publication	Same Calana Lina
Examiner Initials		Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		4,513,006		Maryanoff et al	04/23/1985	
		5,242,942		Costanzo et al	009/07/1993	
		5,384,327		Costanzo et al	01/24/1995	
		5,387,700		Maryanoff et al	02/07/1995	
		6,071,537		Shank	06/06/2000	
		6,130,216		Antonucci et al	10/10/2000	
		6,191,163	B1	Cottrell	02/20/2001	
		`				

Date of Publication Pages, Columns, Lines, Foreign Patent Document of Cited Document where relevant Name of Patentee or passages or relevant Examiner Cite mm-dd-yyyy Applicant of Cited Document figures appear Initials KindCode⁵ Office³ Number⁴ No.1 09/10/1999 wo 99/44581 A2 Ortho-McNeil Pharmaceutical, Inc. wo 00/50020 A2 University of Cincinnati 08/31/2000 Α1 10/12/2000 wo 00/59506 Bristol Myers Squibb Co. 10/19/2000 wo 00/61139 Α1 Ortho-McNeil Pharmaceutical, Inc wo 00/61140 Ortho-McNeil Pharmaceutical, Inc. 10/19/2000 WO 00/76493 Α1 Naiarian 12/21/2000 Bristol Myers Squibb Co. wo 01/27128 04/19/2001 A1

FOREIGN PATENT DOCUMENTS

Examine	er .	Date	
Signatu	re	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document, s Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. e Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 2

a concedent of information annoce it alepiaye	
Application Number	NOT YET ASSIGNED
Filing Date	JANUARY 23, 2004
First Named Inventor	G. CONNOR
Group Art Unit	NOT YET ASSIGNED
Examiner Name	NOT YET ASSIGNED
Attorney Docket Number	ORT-1520-USA-CNT

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
		Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item	[
Examiner's	Cite	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T ²
Initials*	No.1	publisher, city and/or country where published	1
		OSBORNE et al, Topiramate Improves Glycemic Control and Triglycerides in Animal Models. Presented to ADA. Abstracts	
	i	published on line http://www.diabetes.org/am01/AnnualMeeting/Abstracts/AbstractSearch.asp pp 1-11 Abstract.	l
		OSBORNE Figures 6 pages	
		DEMAREST, K. ET AL Topiramate Improves Tolerance and May Improve Insulin Sensitivity in Animal Models of Type 2	
		Diabetes Mellitus. Pages 1-10. Abstract	
		DEMAREST POSTER 6 PAGES Figure 1a to Figure 4	
		CROOKE et al. ABSTRACT, Topiramate Improves Glycemic Control Independent of Weight Loss in ob/ob Mice 1 page	
		DEMAREST ET AL ABSTRACT Topirmate Improves Glucose Tolerance and May Improve Insulin Sensitivity in Animal	1
		Models of Type 2 Diabetes Mellitus 1 page	<u> </u>
		MARKS, Jennifer B., The Insulin Resistance Syndrome, The Monitor, Volume 1, No. 3, Spring 1996.	ļ
		OSBORNE ET AL ABSTRACT Topiramate Improves Glycemic Control and Triglycerides in Animal Models 1 page The	l
		Posters were presented at the Amierican Diabetes Association Conference held June 22-26 in Philadelphia	
		SMITH, ULF ET AL, Topiramate, a novel antiepileptic drug, reduces body weight and food intake in obesity. 1 page Published in Obesity Research Volume 8 (Suppl. 1) Oct 2000	1
		Published in Obesity Research Volume 6 (Suppl. 1) Oct 2000	
			}
			l
	· · · · · · ·		

Examiner	Date	
Examinor		
Signature	Considered	
Olgitature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

SUBMISSION UNDER MPEP 609 D

Application Number NOT YET ASSIGNED
Filing Date JANUARY 23, 2004
First Named Inventor G. CONNOR
Group Art Unit NOT YET ASSIGNED
Examiner Name NOT YET ASSIGNED
Attorney Docket Number ORT-1520-USA-CNT

Page 1 of 1

		1 age 1 of 1			
		U.S. PAT	ENT DOCUMENTS		
			U.S. Patent Docum	nent	Pages, Columns, Lines,
Examiner Initials	Cite No. ¹	Name of Patentee or Applicant of Cited Document	Number	Kind Code ² (if known)	where relevant passages or relevant figures appear
	1				
	 				
	-				
	 				
 -	-				
<u> </u>	 				
	<u> </u>		 		
	<u> </u>				

FOREIGN PATENT DOCUMENTS Pages, Columns, Lines, where relevant passages or relevant figures Foreign Patent Document Name of Patentee or Cite Examiner Applicant of Cited Document Number⁴ KindCode⁵ appear Office³ Initials No.1 OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), T² title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), Cite Examiner volume-issue number(s), publisher, city and/or country where published No.1 Initials* PCT Search Report for PCT/US 01/50840 dated November 13, 2002

Examiner	Date
	Considered Considered
Signature	